U.S. Markets closed

Rigel Pharmaceuticals price target lowered to $10 from $15 at Oppenheimer

Oppenheimer reduced its price target on Rigel after the company and its partner reported mixed Phase IIb results for its fostamatinib drug in rheumatoid arthritis. The firm now sees increased risk that the drug will not demonstrate competitive efficacy in Phase III trials but it maintains an Outperform rating on the stock.